Ocrevus Infusion Reaction Rate
Infusion reactions occur in approximately 34-40% of patients receiving Ocrevus (ocrelizumab), with the vast majority being mild to moderate in severity. 1, 2
Incidence and Severity
Based on the pivotal Phase III trials (OPERA I, OPERA II, and ORATORIO):
- Overall incidence: 34.3% in relapsing MS patients and 39.9% in primary progressive MS patients 2
- Severity breakdown:
- Mild to moderate reactions: >92-97% of all infusion reactions
- Severe reactions: 1.2-2.4% of treated patients
- Serious reactions: Extremely rare (2 cases across all OPERA studies) 2
Timing and Pattern
Infusion reactions occur most commonly with the first infusion, with frequency decreasing substantially with subsequent doses 2. The reactions typically occur during the infusion or within 24 hours post-infusion 1.
Common Symptoms
The most frequently reported infusion reaction symptoms include 2:
- Pruritus (itching)
- Rash
- Throat irritation
- Flushing
- Fatigue
- Headache
Risk Mitigation
Mandatory premedication significantly reduces infusion reaction rates and severity 1:
- 100 mg IV methylprednisolone (or equivalent corticosteroid) 30 minutes before infusion
- Antihistamine (e.g., diphenhydramine) 30-60 minutes before infusion
- Optional antipyretic (e.g., acetaminophen)
Studies demonstrate that antihistamine use is particularly associated with fewer infusion reactions 2.
Shorter Infusion Protocols
Recent studies evaluating 2-hour infusions (versus the standard 3.5-hour protocol) show similar infusion reaction rates of 25-29%, with no increase in severity 3, 4, 5. This indicates that shorter infusion times do not compromise safety while reducing patient burden.
Clinical Management Algorithm
For mild to moderate reactions (most common):
- Reduce infusion rate to half the current rate
- Maintain reduced rate for at least 30 minutes
- Resume at standard rate if tolerated 1
For severe reactions (1-2% of patients):
- Immediately interrupt infusion
- Provide aggressive symptomatic treatment
- Restart only after complete symptom resolution at half the previous rate 1
For life-threatening reactions (extremely rare):
- Immediately stop and permanently discontinue Ocrevus
- Provide appropriate supportive treatment 1